Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report View Sample

Published: August 30, 2022 Report Code: GDGMDHC22303IDB-ST

Select Item

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

The Organophosphate and Carbamate Poisoning pipeline drugs market research report provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects.

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Organophosphate and Carbamate Poisoning pipeline drugs market are Acetylcholinesterase and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA).

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Targets

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Targets

For more Organophosphate and Carbamate Poisoning pipeline drugs market target insights, download a free report sample

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the Organophosphate and Carbamate Poisoning pipeline drugs market are Acetylcholinesterase Activator, Acetylcholinesterase Inhibitor, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist.

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Mechanism of Actions

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Organophosphate and Carbamate Poisoning pipeline drugs market, download a free report sample

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Organophosphate and Carbamate Poisoning pipeline drugs market are inhalational, intramuscular, and oral.

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Routes of Administration

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Organophosphate and Carbamate Poisoning pipeline drugs market, download a free report sample

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Organophosphate and Carbamate Poisoning pipeline drugs market are Small Molecule, Antisense Oligonucleotide, Recombinant Enzyme, and Recombinant Protein.

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Molecule Types

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Organophosphate and Carbamate Poisoning pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Organophosphate and Carbamate Poisoning pipeline drugs market are PlantVax Inc, AntoXa Corp, Countervail Corp, and Shanghai Leado Pharmaceutical Technology Co Ltd.

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Companies

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Analysis, by Companies

To know more about the Organophosphate and Carbamate Poisoning pipeline drugs market companies, download a free report sample

Organophosphate and Carbamate Poisoning Pipeline Drugs Market Report Overview

Key Targets Acetylcholinesterase, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA)
Key Mechanism of Actions Acetylcholinesterase Activator, Acetylcholinesterase Inhibitor, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist)
Key Routes of Administration Inhalational, Intramuscular, and Oral
Key Molecule Types Small Molecule, Antisense Oligonucleotide, Recombinant Enzyme, and Recombinant Protein
Key Companies PlantVax Inc, AntoXa Corp, Countervail Corp, and Shanghai Leado Pharmaceutical Technology Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning.
  • Reviews of pipeline therapeutics for Organophosphate and Carbamate Poisoning by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Organophosphate and Carbamate Poisoning therapeutics and enlists all their major and minor projects.
  • Evaluation of Organophosphate and Carbamate Poisoning therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with the potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning.

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AntoXa Corp
Countervail Corp
PlantVax Inc
Shanghai Leado Pharmaceutical Technology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Organophosphate and Carbamate Poisoning – Overview

Organophosphate and Carbamate Poisoning – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Organophosphate and Carbamate Poisoning – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Organophosphate and Carbamate Poisoning – Companies Involved in Therapeutics Development

AntoXa Corp

Countervail Corp

PlantVax Inc

Shanghai Leado Pharmaceutical Technology Co Ltd

Organophosphate and Carbamate Poisoning – Drug Profiles

AM-132 – Drug Profile

Product Description

Mechanism Of Action

galantamine hydrobromide – Drug Profile

Product Description

Mechanism Of Action

History of Events

LD-04001 – Drug Profile

Product Description

Mechanism Of Action

PlantVax-1502-HN – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Butyrylcholinesterase for Carbamate and Organophosphate Poisoning – Drug Profile

Product Description

Mechanism Of Action

History of Events

RS-194B – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Organophosphate Poisoning – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning – Drug Profile

Product Description

Mechanism Of Action

Organophosphate and Carbamate Poisoning – Dormant Projects

Organophosphate and Carbamate Poisoning – Discontinued Products

Organophosphate and Carbamate Poisoning – Product Development Milestones

Featured News & Press Releases

Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Toxicology reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more